Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEADE PanTumor study of precemtabart tocentecan (M9140) in advanced solid tumors
CTR20250902Phase 2Suspended
- Sponsor
- Merck KGaA
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of precemtabart tocentecan in non-small cell lung cancer (NSCLC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma (PDAC), Nonhematologic neoplasms, sponsored by Merck KGaA. Started Dec 2025; status: suspended.
02
Drugs
precemtabart tocentecan
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20250902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250902.